{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:50:43Z","timestamp":1790819443122,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.mayocp.2011.09.001","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T17:32:52Z","timestamp":1326130372000},"page":"67-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["My Treatment Approach to Hairy Cell Leukemia"],"prefix":"10.1016","volume":"87","author":[{"given":"Rahul R.","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Saven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mayocp.2011.09.001_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM197102182840704","article-title":"Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis","volume":"284","author":"Yam","year":"1971","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2011.09.001_bib2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.mayocp.2011.09.001_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2011.09.001_bib4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2009-10-251645","article-title":"Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine","volume":"115","author":"Sigal","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.001_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V61.2.349.349","article-title":"Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement","volume":"61","author":"Golomb","year":"1983","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2011.09.001_bib6","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/1097-0142(19851201)56:11<2557::AID-CNCR2820561103>3.0.CO;2-T","article-title":"Hairy cell leukemia: durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients","volume":"56","author":"Magee","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.001_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.001_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","article-title":"Treatment of hairy cell leukemia with recombinant alpha-interferon","volume":"68","author":"Quesada","year":"1986","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2011.09.001_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2011.09.001_bib10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1984.2.12.1336","article-title":"Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin)","volume":"2","author":"Spiers","year":"1984","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.001_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1989.7.2.168","article-title":"Pentostatin in the treatment of advanced hairy cell leukemia","volume":"7","author":"Kraut","year":"1989","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.mayocp.2011.09.001_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2011.09.001_bib13","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2011.09.001_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.001_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2005-01-0173","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience","volume":"106","author":"Chadha","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2011.09.001_bib16","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.leu.2403418","article-title":"An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine","volume":"18","author":"Jehn","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2011.09.001_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.1995.13.4.989","article-title":"Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia","volume":"13","author":"Juliusson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2011.09.001_bib18","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/annonc\/mdf272","article-title":"Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study","volume":"13","author":"von Rohr","year":"2002","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2011.09.001_bib19","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V89.5.1838","article-title":"Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications","volume":"89","author":"Lauria","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.001_bib20","first-page":"22","article-title":"Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications","volume":"84","author":"Lauria","year":"1999","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.mayocp.2011.09.001_bib21","first-page":"309","article-title":"Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine","volume":"89","author":"Zinzani","year":"2004","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.mayocp.2011.09.001_bib22","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood-2006-08-042929","article-title":"Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial","volume":"109","author":"Robak","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2011.09.001_bib23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10428190903131755","article-title":"Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32\/98)","volume":"50","author":"Zenhausern","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.mayocp.2011.09.001_bib24","article-title":"Analysis of toxicity and efficacy of subcutaneous cladribine at reduced or standard doses (five versus seven consecutive days) in patients with hairy cell leukemia (HCL) in the ICGHCL2004 Protocol by the Italian Cooperative Group on HCL [ASH abstract 701]","volume":"116","author":"Forconi","year":"2010","journal-title":"Blood"},{"issue":"8825","key":"10.1016\/j.mayocp.2011.09.001_bib25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2011.09.001_bib26","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood.V84.12.4061.bloodjournal84124061","article-title":"Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin","volume":"84","author":"Kraut","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.001_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<65::AID-CNCR9>3.0.CO;2-B","article-title":"Long term outcome of patients with hairy cell leukemia treated with pentostatin","volume":"85","author":"Ribeiro","year":"1999","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2011.09.001_bib28","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2011.09.001_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients","volume":"17","author":"Maloisel","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.001_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2141.1999.01546.x","article-title":"Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine","volume":"106","author":"Dearden","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.mayocp.2011.09.001_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.mayocp.2011.09.001_bib32","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2003-01-0014","article-title":"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia","volume":"102","author":"Nieva","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2011.09.001_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2141.2001.03143.x","article-title":"Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia","volume":"115","author":"Hagberg","year":"2001","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2011.09.001_bib34","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3324\/haematol.11564","article-title":"Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31\/98)","volume":"93","author":"Zenhausern","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.mayocp.2011.09.001_bib35","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukemia","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2011.09.001_bib36","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2005-11-4590","article-title":"Eradication of minimal residual disease in hairy cell leukemia","volume":"107","author":"Ravandi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2011.09.001_bib37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2458.2458","article-title":"Phase II study of sequential therapy with cladribine followed by an extended course rituximab in patients with hairy cell leukemia [ASH abstract 2458]","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2011.09.001_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2141.2008.07333.x","article-title":"Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up","volume":"143","author":"Cervetti","year":"2008","journal-title":"Br J Haematol"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2011.09.001_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10428194.2011.568650","article-title":"Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence","volume":"52","author":"Else","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.mayocp.2011.09.001_bib40","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V93.8.2471","article-title":"Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia","volume":"93","author":"Saven","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2011.09.001_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2011.09.001_bib42","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2011.09.001_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2516.2516","article-title":"A phase 1 study of moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin, in relapsed\/refractory hairy cell leukemia (HCL): updated results [ASH abstract 2516]","volume":"116","author":"Kreitman","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2011.09.001_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.thj.6200373","article-title":"Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment","volume":"5","author":"Fietz","year":"2004","journal-title":"Hematol J"},{"issue":"6","key":"10.1016\/j.mayocp.2011.09.001_bib45","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3109\/10428194.2011.562575","article-title":"Response of hairy cell leukemia to bendamustine","volume":"52","author":"Kreitman","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.mayocp.2011.09.001_bib46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle","year":"1958","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T02:59:53Z","timestamp":1675911593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0025619611000085"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.09.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"My Treatment Approach to Hairy Cell Leukemia","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2011.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}